Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Grabowski

Showing results (61-70 of 128) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|October 26, 2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher diseaseNeal J Weinreb, John A Barranger, Joel Charrow, et al.
Human Molecular Genetics|August 3, 2019
Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher diseaseYanyan Peng, Benjamin Liou, Venette Inskeep, et al.
Human Molecular Genetics|March 14, 2007
Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin traffickingYing Sun, David P Witte, Matt Zamzow, et al.
Blood|March 11, 2004
Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapyRichard J Wenstrup, Laurie Bailey, Gregory A Grabowski, et al.
The Journal of Cell Biology|May 26, 2010
The role of UDP-Glc:glycoprotein glucosyltransferase 1 in the maturation of an obligate substrate prosaposinBradley R Pearse, Taku Tamura, Johan C Sunryd, et al.
American Journal of Hematology|February 4, 2014
Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014John A Barranger, Roscoe O Brady, Gregory A Grabowski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesionsJukka K Hakala, Riina Oksjoki, Petri Laine, et al.
Journal of Lipid Research|August 28, 2007
Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophagesDongFang Wu, Chakradhari Sharan, Hong Yang, et al.
The Journal of Pediatrics|January 24, 2007
Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapyT Andrew Burrow, Mitchell B Cohen, Ronald Bokulic, et al.
Molecular Genetics and Metabolism|October 2, 2013
Gaucher disease: chemotactic factors and immunological cell invasion in a mouse modelManoj Kumar Pandey, Nicholas A Jabre, You-Hai Xu, et al.
Pageof 13

Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|October 26, 2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher diseaseNeal J Weinreb, John A Barranger, Joel Charrow, et al.
Human Molecular Genetics|August 3, 2019
Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher diseaseYanyan Peng, Benjamin Liou, Venette Inskeep, et al.
Human Molecular Genetics|March 14, 2007
Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin traffickingYing Sun, David P Witte, Matt Zamzow, et al.
Blood|March 11, 2004
Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapyRichard J Wenstrup, Laurie Bailey, Gregory A Grabowski, et al.
The Journal of Cell Biology|May 26, 2010
The role of UDP-Glc:glycoprotein glucosyltransferase 1 in the maturation of an obligate substrate prosaposinBradley R Pearse, Taku Tamura, Johan C Sunryd, et al.
American Journal of Hematology|February 4, 2014
Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014John A Barranger, Roscoe O Brady, Gregory A Grabowski, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesionsJukka K Hakala, Riina Oksjoki, Petri Laine, et al.
Journal of Lipid Research|August 28, 2007
Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophagesDongFang Wu, Chakradhari Sharan, Hong Yang, et al.
The Journal of Pediatrics|January 24, 2007
Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapyT Andrew Burrow, Mitchell B Cohen, Ronald Bokulic, et al.
Molecular Genetics and Metabolism|October 2, 2013
Gaucher disease: chemotactic factors and immunological cell invasion in a mouse modelManoj Kumar Pandey, Nicholas A Jabre, You-Hai Xu, et al.
Pageof 13